Tavapadon

Unassigned

New Medicines

Early-stage Parkinson's disease or as adjunctive therapy to levodopa in patients with late-stage disease with motor fluctuations

Information

New molecular entity
Cerevel Therapeutics
Cerevel Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective partial agonist of dopamine D1 and D5 receptors
Parkinson disease typically develops between the ages of 55 and 65 years and occurs in 1-2% of people over the age of 60 years, rising to 3.5% at age 85-89 years [2].
Early-stage Parkinson's disease or as adjunctive therapy to levodopa in patients with late-stage disease with motor fluctuations
Oral